XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 32.18

-0.4%

Nov 28 12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: charles moore who wrote (6992)	8/26/1998 11:25:00 AM
From: aknahow	Read Replies (1) of 17367

The importance is probably in providing a means of faster diagnosis. The financial impact while a positive is IMO, will be, very minor even using very generous estimates. biz.yahoo.com Assuming the LBP test somehow becomes 10% of DPC sales one is only talking about $18 million. Even if the royalty is 5% one is looking at a maximum of $900,000 to XOMA per year at some future date. Cut this in half to be conservative and one is probably closer to something attainable. Nonetheless, I think this development is important for the reasons give by Castello, potential better trial design and faster treatment of sepsis, with yes, Neuprex if and when approved.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next